Published in Medical Letter on the CDC and FDA, May 16th, 2010
"We restricted analyses to patients whom we considered eligible for GPT (i.e., had a documented HIV viral load > 1000 copies/mL). We used multivariable general modeling to evaluate temporal trends in use of GPT among eligible patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.